MISSION

The Group is focused on Hodgkin Lymphoma (HL), a rare cancer. When treated correctly, HL can be cured, but late toxicity (second cancers, cardiovascular diseases and fatigue) is a major concern. New trial initiatives aim to reduce both acute and late toxicity, whilst maintaining high cure rates. Research assesses all aspects of the disease to achieve a better basis for personalised treatment.

PRACTICE CHANGING RESEARCH

  • Lymphoma Group

    EORTC 20012 – BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin’s Lymphoma.

    Building off of the results of EORTC trials H9,10, and 12, in 2016, this EORTC trial compared two different chemotherapy regiments (ABVD 8 and BEACOPP 4 + 4) and found similar results in event-free and overall survival in patients with high-risk advanced-stage Hodgkin’s Lymphoma.

    READ MORE

  • Feb-17

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up